InVivo Therapeutics Holdings Corp. (NVIV) today announced the
appointment of Mark D. Perrin as Chief Executive Officer, effective
January 6, 2014. Upon his appointment, Mr. Perrin will also become a
member of the Board of Directors.
Mr. Perrin most recently served as President of Dennan Consulting, a
biotech consulting firm. From 2005 to 2010, he served as President and
Chief Executive Officer of ConjuChem Biotechnologies. From 2002 to 2005,
he was Executive Vice President and Chief Commercial Officer for Orphan
Medical, until it was acquired by Jazz Pharmaceuticals. From 1995 to
2001, he was Executive Vice President, Commercial Operations for COR
Therapeutics. Earlier in his career he was Vice President for Burroughs
Wellcome and for Lederle Laboratories, with responsibility for U.S.
commercial operations at each company.
InVivo Chairman John McCarthy said, “Mark is an excellent fit for
InVivo. His extensive commercial background will be invaluable to
portfolio decisions for our novel hydrogel technology and our new
emphasis on partnering as a primary way to finance new programs. He also
has solid experience raising money, which will be important to us as we
continue to focus our critical resources on high-value opportunities
that maximize long-term value for our shareholders. Importantly, Mark
has the integrity, strategic vision and work ethic to take InVivo to the
next level.”
Mr. McCarthy added, “I also want to acknowledge the accomplishments of
our Interim Chief Executive Officer, Mike Astrue. In August of this
year, Mike stepped into a difficult situation on very short notice. He
moved our stalled lead clinical program forward at an impressive rate,
developed a new business plan designed to reduce risk and increase
shareholder value, initiated a series of important business development
discussions, and added a first class-team of permanent executives,
interim executives, and consultants that has greatly improved management
of the company. It’s been a true pleasure working closely with Mike over
the past five months, and on behalf of the full Board and employee base,
we extend our thanks and appreciation for all his great work.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company
with unique technologies for drug delivery with a focus on treatment of
spinal cord injuries. The Company was founded in 2005 with proprietary
technology co-invented by Robert Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
is affiliated with Massachusetts General Hospital. In 2011 the Company
earned the David S. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury
medicine. The publicly traded company is headquartered in Cambridge, MA.
For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. Any forward-looking statements
contained herein are based on current expectations, but are subject to a
number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include,
but are not limited to, risks and uncertainties relating to the
Company’s ability to obtain FDA approval of its revised protocol and the
timing thereof; the identification of appropriate clinical sites; the
Institutional Review Board process; the Company’s ability to enter into
partnerships; the Company’s ability to obtain FDA approval to
commercialize its products; the Company’s ability to develop, market and
sell products based on its technology; the expected benefits and
efficacy of the Company’s products and technology in connection with
spinal cord injuries; the availability of substantial additional funding
for the Company to continue its operations and to conduct research and
development, clinical studies and future product commercialization; and
other risks associated with the Company’s business, research, product
development, regulatory approval, marketing and distribution plans and
strategies identified and described in more detail in our filings with
the SEC, including our Form 10-K and 10-Qs and our current reports on
Form 8-K. We do not undertake to update these forward-looking statements
made by us.
Copyright Business Wire 2013